Transthyretin Stabilizers Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Ionis Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Akcea Therapeutics, Inc.
- Eidos Therapeutics, Inc.
- FoldRx Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- Prothena Corporation plc
- Ionis/Biogen
- Coherus BioSciences, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of transthyretin stabilizers is evaluated at USD 16.45 billion.
The global transthyretin stabilizers market size was worth more than USD 15.23 billion in 2025 and is poised to witness a CAGR of over 8.9%, crossing USD 35.73 billion revenue by 2035.
Asia Pacific transthyretin stabilizers market is expected to capture the largest share of 40%, driven by the adoption of telehealth and remote patient monitoring solutions enhancing access and disease management.
Key players in the market include Pfizer Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Akcea Therapeutics, Inc., Eidos Therapeutics, Inc., FoldRx Pharmaceuticals, Inc.
